Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Sees Large Drop in Short Interest

Carl Zeiss Meditec AG (OTCMKTS:CZMWYGet Free Report) saw a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 37 shares, a decline of 96.4% from the June 30th total of 1,033 shares. Based on an average daily volume of 7,749 shares, the days-to-cover ratio is currently 0.0 days.

Carl Zeiss Meditec Trading Up 1.1%

Shares of OTCMKTS:CZMWY traded up $0.33 during trading on Friday, reaching $31.40. The company had a trading volume of 650 shares, compared to its average volume of 4,705. The stock’s fifty day moving average price is $30.96 and its 200 day moving average price is $32.20. Carl Zeiss Meditec has a fifty-two week low of $26.65 and a fifty-two week high of $60.10.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Carl Zeiss Meditec from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. One research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Get Our Latest Stock Report on CZMWY

Carl Zeiss Meditec Company Profile

(Get Free Report)

Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.

The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.

Featured Stories

Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.